John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at Follow @JohnCFierce on Twitter.

Articles by John Carroll

AstraZeneca teams with tiny Cerulean on an NCI cancer combo study

AstraZeneca is teaming up with Cambridge, MA-based Cerulean, launching a combo study that marries the biotech's nano-polymer drug conjugate with the pharma giant's Lynparza (the PARP inhibitor olaparib) to test its synergistic effects on tumors. And the National Cancer Institute is stepping in to fund the study and carry it out.

Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus

Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, Williams signed on as "employee number one" of Codiak BioSciences, which now has an $80 million-plus commitment from some prominent early-stage investors to launch a quest into the role exosomes can play in treating cancer and a wide variety of other diseases.

J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex

Johnson & Johnson scored an early FDA approval for its "breakthrough" blockbuster contender daratumumab, earning a swift OK as a new treatment for multiple myeloma four months ahead of the PDUFA date. The drug will be marketed as Darzalex.

Genfit launches a PhIII study for NASH drug

France's Genfit says it is preparing to launch its Phase III study of the NASH drug elafibranor. The biotech plans to recruit 1,800 patients for the study at 200 centers worldwide.

UPDATED: Clovis Oncology shares crash after lung cancer response rate deteriorates

Clovis Oncology says that the FDA demanded fresh efficacy data for the lung cancer drug rociletinib (CO-1686) in order to complete its review. And while the biotech plans to hand that over today, it adds that the fresh data include a worse response rate than expected and could force a delay in the accelerated March 30, 2016, deadline that the FDA had set for a marketing decision.

RIP: Failure-prone KaloBios pulls the plug, calls in the liquidators

Failure-prone KaloBios--which launched with a repeated reassurance to investors that developing antibodies had become a lot easier--says that after a brief look at alternative scenarios the best next step now is to wind down operations.

UPDATED: AstraZeneca wins big with fast FDA OK of AZD9291 for lung cancer

AstraZeneca gained a crucial accelerated FDA approval for its targeted lung cancer drug AZD9291 today, offering tangible evidence of the R&D turnaround CEO Pascal Soriot had promised investors several years ago. And now the drug, to be marketed as Tagrisso, will be put to the market test to see if it can live up to Soriot's $3 billion peak sales estimate while staring down a strong rival in late-stage development at Clovis Oncology.

Auven Therapeutics pits rival PhIII dry eye drug against Allergan, Shire

Auven Therapeutics has staked a late-stage claim on a share of the dry eye market, posting some mixed Phase IIb/III data that included hitting a statistically significant improvement on a key measure of the increasingly common ailment.

China's new pharma crackdown may help top companies

China's Food and Drug Administration is cracking down on drugmakers, rejecting 11 applications for generic treatments in a move widely seen as an effort to bolster confidence in the country's biopharma industry by demanding that players meet higher standards.

UPDATED: Gilead, Sanofi singled out as worst offenders in failing to disclose trial data

When it comes to publishing a full set of trial data on new drugs, the biopharma industry overall has a poor record on transparency, according to a new report from a bioethics watchdog group. And some companies--like Sanofi and Gilead--fall well below the "legal and ethical" standards on this score.